TY  - BOOK
AU  - Campbell, Wayne
TI  - ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY
SN  - 1935-1089
PY  - 2018///
KW  - *Adalimumab/ae [Adverse Effects]
KW  - *Anti-Inflammatory Agents/ae [Adverse Effects]
KW  - *Retinal Necrosis Syndrome, Acute/ci [Chemically Induced]
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]
KW  - MedStar Union Memorial Hospital
KW  - Medicine
KW  - Case Reports
KW  - Journal Article
N1  - Available online through MWHC library: 2007 - present
N2  - CONCLUSION: Physicians prescribing tumor necrosis factor alpha antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis; METHODS: Case report; PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor alpha immunosuppressive therapy; RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor alpha antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment
UR  - https://dx.doi.org/10.1097/ICB.0000000000000499
ER  -